Truist lowered the firm’s price target on Crispr Therapeutics (CRSP) to $120 from $160 and keeps a Buy rating on the shares. Based on the recent comments from Vertex Pharmaceuticals (VRTX), the firm is reducing its CASGEVY uptake assumptions, the analyst tells investors in a research note. Despite activation of three additional treatment centers for total of 12 in the U.S., first patient dosing has not commenced yet with first patient dosing expected to start in “weeks”, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRSP:
- Cathie Wood’s ARK Investment bought 167K shares of Crispr Therapeutics today
- Crispr Therapeutics announces FDA approval for Casgevy
- CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
- Crispr Therapeutics call volume above normal and directionally bullish
- Baird finds ‘incremental negative’ in Crispr’s 2024 outlook